Sintilimab is an anti-programmed cell death receptor-1 antibody. The phase III clinical trial ORIENT-12 confirmed the safety of sintilimab combined with pemetrexed/platinum in the treatment of advanced squamous non-small cell lung cancer. Skin reactions are the most commonly reported adverse events of immune checkpoint inhibitors and are rarely severe.
View Article and Find Full Text PDFThe seismo-electrical coupling is critical to understand the mechanism of geoelectrical precursors to earthquakes. A novel seismo-electrical model, called Chen-Ouillon-Sornette (COS) model, has been developed by combining the Burridge-Knopoff spring-block system with the mechanisms of stress-activated charge carriers (i.e.
View Article and Find Full Text PDFJ Infect Public Health
November 2018
This study was undertaken to investigate the relationship between cerebrospinal fluid abnormalities and prognosis in pediatric refractory purulent meningitis. Ninety cases of pediatric refractory purulent meningitis were stratified into "good" (n=33) or "poor" (n=57) prognosis groups according to the Glasgow clinical outcome scores. The symptoms, laboratory results, and prognosis were compared by using univariate and multivariate logistic regression analyses.
View Article and Find Full Text PDF